Clinical parameters, anemia, and spleen response in patients with MF-related anemia treated with luspatercept: Efficacy sub-analysis from the ACE-536-MF-001 study

According to data from the phase 2 ACE-536-MF-001 study—presented during the 2023 American Society of Hematology Annual Meeting—luspatercept demonstrated improvement in transfusion burden in patients with myelofibrosis. Among patients with transfusion-dependent disease, transfusion independence at ≥ 12 weeks was observed in 19.0% (95% CI: 5.45–41.91) of those not receiving concurrent ruxolitinib and 31.6% (95% CI: 17.5–48.7) of those receiving concurrent ruxolitinib, respectively, in the entire treatment period.